Skip to main content

Published locations for FDA approves higher dose brigatinib tablet for advanced ALK+ NSCLC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. FDA approves higher dose brigatinib tablet for advanced ALK+ NSCLC

User login

  • Reset your password
  • /content/fda-approves-higher-dose-brigatinib-tablet-advanced-alk-nsclc
  • /oncologypractice/article/148629/lung-cancer/fda-approves-higher-dose-brigatinib-tablet-advanced-alk
  • /node/155702/article/148629/lung-cancer/fda-approves-higher-dose-brigatinib-tablet-advanced-alk-nsclc
  • /hematology-oncology/article/148629/lung-cancer/fda-approves-higher-dose-brigatinib-tablet-advanced
  • /chestphysician/article/148629/lung-cancer/fda-approves-higher-dose-brigatinib-tablet-advanced-alk